



EFPIA Code Disclosure 2022 Self-Certification Scheme

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Boehringer Ingelheim works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Boehringer Ingelheim hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2021 have been reported in application of the EFPIA Code following key principles:

Disclosure quality

Boehringer Ingelheim certifies that:

- Its disclosures are made in each country covered by the EFPIA Code where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes

Boehringer Ingelheim certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Aggregate disclosures are limited to Research and Development ToVs and such HCPs/HCOs' ToVs that cannot be disclosed on an individual basis for legal reasons

Boehringer Ingelheim certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.


Ensuring compliance with Data Privacy Obligations

Boehringer Ingelheim certifies that its disclosure complies with the Data Privacy obligations.

Date: 09-Jun-2022

Name of signatory: Hubertus von Baumbach

Position in the Company: Chairman of the Board of Managing Directors

Signature: 8DC533643739466...

Certificate Of Completion

Envelope Id: D7FACDD46B8C4895AFA6D5FCB537FC1D	Status: Completed
Subject: EFPIA Disclosure Code - Self-Certification Letter 2022	
Source Envelope:	
Document Pages: 2	Signatures: 1
Certificate Pages: 4	Initials: 0
AutoNav: Enabled	Envelope Originator:
Enveloped Stamping: Enabled	Katharina Barner
Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna	Binger Straße 173
	Ingelheim, Rheinland-Pfalz CT 55216
	katharina.barner@boehringer-ingelheim.com
	IP Address: 147.161.164.113


Record Tracking

Status: Original	Holder: Katharina Barner	Location: DocuSign
6/9/2022 11:50:10 AM		
	katharina.barner@boehringer-ingelheim.com	

Signer Events

Hubertus Baumbach
 hubertus.von_baumbach@boehringer-ingelheim.com
 m
 Boehringer Ingelheim Standard
 Security Level: Email, Account Authentication (None)

Signature

DocuSigned by:

 8DC533643739466...
 Signature Adoption: Pre-selected Style
 Signed by link sent to hubertus.von_baumbach@boehringer-ingelheim.com
 Using IP Address: 147.161.164.127

Timestamp

Sent: 6/9/2022 12:01:53 PM
 Viewed: 6/9/2022 12:40:07 PM
 Signed: 6/9/2022 12:40:59 PM

Electronic Record and Signature Disclosure:

Accepted: 11/16/2021 4:14:24 AM
 ID: faf5e6d4-3878-40de-92a6-8e939ffb8f15

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp

Carbon Copy Events

Status

Timestamp

Katharina Barner
 katharina.barner@boehringer-ingelheim.com
 Boehringer Ingelheim
 Security Level: Email, Account Authentication (None)

COPIED

Sent: 6/9/2022 12:41:01 PM
 Resent: 6/9/2022 12:41:02 PM
 Viewed: 6/10/2022 7:27:07 AM

Electronic Record and Signature Disclosure:

Accepted: 3/23/2022 10:16:29 AM
 ID: 3b51159f-a3df-4477-a703-02c35e26d026

Nicola Galtieri
 nicola.galtieri@boehringer-ingelheim.com
 DR
 Boehringer Ingelheim
 Security Level: Email, Account Authentication (None)

COPIED

Sent: 6/9/2022 12:41:01 PM
 Viewed: 6/10/2022 10:16:30 AM

Electronic Record and Signature Disclosure:

Carbon Copy Events	Status	Timestamp
---------------------------	---------------	------------------

Accepted: 11/24/2021 2:03:15 PM
ID: 43025299-0c8d-4335-8100-ec8e7e3320a8

Witness Events	Signature	Timestamp
-----------------------	------------------	------------------

Notary Events	Signature	Timestamp
----------------------	------------------	------------------

Envelope Summary Events	Status	Timestamps
--------------------------------	---------------	-------------------

Envelope Sent	Hashed/Encrypted	6/9/2022 12:01:53 PM
Certified Delivered	Security Checked	6/9/2022 12:40:07 PM
Signing Complete	Security Checked	6/9/2022 12:40:59 PM
Completed	Security Checked	6/9/2022 12:41:01 PM

Payment Events	Status	Timestamps
-----------------------	---------------	-------------------

Electronic Record and Signature Disclosure

Boehringer Ingelheim Consent to Proceed with Electronic Signatures

This document describes the frame conditions with regard to the use of the DocuSign® system by the authorized user ('you') for electronic signing and/or processing of documents concerning the business with Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany or any of its affiliated companies ('we, us or Company').

Via the DocuSign® system, you will be able to complete, review, and even print documents you will electronically sign using only your web browser via the link sent to you by e-mail. Before using the DocuSign® system, please make sure that you are able to meet the technical system requirements, which can be accessed via the DocuSign® website. Please read the information below carefully and thoroughly.

Contractual documents and notices may be sent to you electronically

If not otherwise agreed in a given contract between you and us, we will provide electronically to you through your DocuSign® user account all contractual documents, notices and other documents that are required to be provided or made available to you during the course of our business relationship with you. To reduce the chance of you inadvertently not receiving any notice or document, we will provide all of the required notices and documents to you by the contractually agreed method(s) and to the address(es) provided therein. Subject to the provisions of the given contract you may receive documents and notices electronically or in paper format.

Getting paper copies

As long as you are an authorized user of the DocuSign® system, you will have the ability to download and print any documents we send to you through your DocuSign® user account for a limited period of time (usually 30 calendar days) after such documents are first sent to you. In case a mandatory local legal requirements exists, we will provide paper copies of the contractual documents upon your request which has to be sent to the respective Company contact nominated in the contract.

Consequences of changing your mind

In exceptional cases (f.e. contractually agreed option, mandatory local legal requirement) you may be entitled to elect to receive required notices and disclosures only or additionally in paper format. If you decide to exercise a given option you have to liaise with your respective Company contact nominated in the contract by using the address(es) in accordance with the process contractually foreseen.

Changing your e-mail address

If your e-mail address changes please arrange for your new e-mail address to be reflected in your DocuSign® account by following the process for changing e-mail in the DocuSign® system.

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, please verify that you were able to read this electronic consent and that you (i) also were able to print on paper or electronically save this disclosure for your future reference and access or that you (ii) were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access.

By checking the 'I Agree' box, I confirm that:

- I can access and read this CONSENT TO PROCEED WITH ELECTRONIC SIGNATURES document; and

- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I have notified my respective Company contact as described above, I consent to receive through electronic means all contractual documents, notices and other documents that are required to be provided or made available to me by the Company during the course of the business relationship with you.